PL1833805T3 - Nowe pochodne kwasu 3-fenylopropionowego do leczenia cukrzycy - Google Patents

Nowe pochodne kwasu 3-fenylopropionowego do leczenia cukrzycy

Info

Publication number
PL1833805T3
PL1833805T3 PL05826447T PL05826447T PL1833805T3 PL 1833805 T3 PL1833805 T3 PL 1833805T3 PL 05826447 T PL05826447 T PL 05826447T PL 05826447 T PL05826447 T PL 05826447T PL 1833805 T3 PL1833805 T3 PL 1833805T3
Authority
PL
Poland
Prior art keywords
alkyl
acid derivatives
phenylpropionic acid
aryl
new
Prior art date
Application number
PL05826447T
Other languages
English (en)
Inventor
Zbigniew Majka
Tomasz Stawiński
Katarzyna Rusin
Andrzej Sawicki
Krzysztof Kurowski
Katarzyna Matusiewicz
Daniel Sulikowski
Piotr Kowalczyk
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of PL1833805T3 publication Critical patent/PL1833805T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
PL05826447T 2004-12-20 2005-12-16 Nowe pochodne kwasu 3-fenylopropionowego do leczenia cukrzycy PL1833805T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL371841A PL371841A1 (pl) 2004-12-20 2004-12-20 Nowe związki pochodne kwasu 3-fenylopropionowego
PCT/EP2005/056839 WO2006067086A1 (en) 2004-12-20 2005-12-16 New 3-phenylpropionic acid derivatives for the treatment of diabetes
EP05826447A EP1833805B1 (en) 2004-12-20 2005-12-16 New 3-phenylpropionic acid derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
PL1833805T3 true PL1833805T3 (pl) 2010-04-30

Family

ID=36118603

Family Applications (2)

Application Number Title Priority Date Filing Date
PL371841A PL371841A1 (pl) 2004-12-20 2004-12-20 Nowe związki pochodne kwasu 3-fenylopropionowego
PL05826447T PL1833805T3 (pl) 2004-12-20 2005-12-16 Nowe pochodne kwasu 3-fenylopropionowego do leczenia cukrzycy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL371841A PL371841A1 (pl) 2004-12-20 2004-12-20 Nowe związki pochodne kwasu 3-fenylopropionowego

Country Status (25)

Country Link
US (2) US7312338B2 (pl)
EP (1) EP1833805B1 (pl)
JP (1) JP2008524166A (pl)
KR (1) KR100923199B1 (pl)
CN (1) CN101084203A (pl)
AT (1) ATE457305T1 (pl)
AU (1) AU2005318221B2 (pl)
BR (1) BRPI0519584A2 (pl)
CA (1) CA2588662C (pl)
CY (1) CY1110622T1 (pl)
DE (1) DE602005019327D1 (pl)
DK (1) DK1833805T3 (pl)
ES (1) ES2341020T3 (pl)
HR (1) HRP20100079T1 (pl)
IL (1) IL183563A0 (pl)
MX (1) MX2007007452A (pl)
NO (1) NO20073736L (pl)
PL (2) PL371841A1 (pl)
PT (1) PT1833805E (pl)
RS (1) RS51228B (pl)
RU (1) RU2360906C2 (pl)
SI (1) SI1833805T1 (pl)
UA (1) UA89807C2 (pl)
WO (1) WO2006067086A1 (pl)
ZA (1) ZA200704584B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
ME03573B (me) * 2012-05-04 2020-07-20 Samumed Llc 1H-PIRAZOLO[3,4-B]PIRIDINI l NJIHOVA TERAPEUTSKA UPOTREBA
KR20220138654A (ko) * 2021-04-06 2022-10-13 주식회사 온코크로스 당뇨병의 예방 또는 치료용 화합물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58125039A (ja) 1982-01-21 1983-07-25 Konishiroku Photo Ind Co Ltd 写真用２当量イエロ−カプラ−
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
NZ253742A (en) * 1992-07-03 1997-06-24 Smithkline Beecham Plc Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions
AU1961695A (en) 1994-03-12 1995-10-03 Yuhan Corporation Triazole compounds and processes for the preparation thereof
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
ATE260912T1 (de) 1999-09-08 2004-03-15 Glaxo Group Ltd Oxazol ppar antagonisten
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
JP2004536152A (ja) 2001-07-30 2004-12-02 ノボ　ノルディスク　アクティーゼルスカブ 新規ビニルｎ−（２−ベンゾイルフェニル）−ｌ−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
JP2005503377A (ja) 2001-07-30 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ 新規ビニルｎ−（２−ベンゾイルフェニル）−ｌ−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
EP1480957A1 (en) * 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
PL371841A1 (pl) 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego

Also Published As

Publication number Publication date
EP1833805B1 (en) 2010-02-10
BRPI0519584A2 (pt) 2009-02-17
US20070219259A1 (en) 2007-09-20
HRP20100079T1 (hr) 2010-04-30
RU2360906C2 (ru) 2009-07-10
CN101084203A (zh) 2007-12-05
MX2007007452A (es) 2007-11-07
RU2007127724A (ru) 2009-01-27
PL371841A1 (pl) 2006-06-26
UA89807C2 (ru) 2010-03-10
CA2588662A1 (en) 2006-06-29
ATE457305T1 (de) 2010-02-15
CY1110622T1 (el) 2015-04-29
KR100923199B1 (ko) 2009-10-22
JP2008524166A (ja) 2008-07-10
RS51228B (sr) 2010-12-31
IL183563A0 (en) 2007-09-20
US7919515B2 (en) 2011-04-05
DE602005019327D1 (de) 2010-03-25
KR20070097057A (ko) 2007-10-02
CA2588662C (en) 2010-12-07
EP1833805A1 (en) 2007-09-19
AU2005318221A1 (en) 2006-06-29
ES2341020T3 (es) 2010-06-14
US7312338B2 (en) 2007-12-25
WO2006067086A1 (en) 2006-06-29
NO20073736L (no) 2007-07-18
ZA200704584B (en) 2008-10-29
US20070088061A1 (en) 2007-04-19
AU2005318221B2 (en) 2009-09-17
DK1833805T3 (da) 2010-05-17
SI1833805T1 (sl) 2010-05-31
PT1833805E (pt) 2010-03-31

Similar Documents

Publication Publication Date Title
MY142807A (en) Benzimidazole derivative and use thereof.
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
TW200407309A (en) 1,2-Azole derivatives
DE60221098D1 (de) Kondensierte heterocyclische derivate
NZ514487A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
CA2336412A1 (en) Medicament for treatment of diabetes
WO2004048340A8 (en) Sinomenine and sinomenine compounds, synthesis and use
CY1110622T1 (el) Νεα παραγωγα 3-φαινυλοπροπιονικου οξεος για την αντιμετωπιση του διαβητη
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20050087L (no) N-benzoylureido-kanelsyrederivater, fremgangsmate for fremstilling og anvendelse av disse
ZA200705889B (en) New 3-phenylpropionic acid derivatives and their use as PPAR-GAMMA receptor ligands
UA81640C2 (ru) Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе
WO2003028732A1 (en) Receptor antagonist
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
JP2004502773A5 (pl)
WO2008146917A1 (ja) リンコマイシン誘導体及びこれを有効成分とする抗菌剤
ATE386735T1 (de) Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung
CA2487450A1 (en) (2s)-2-ethylphenylpropanoic acid derivatives
RU2007122499A (ru) Новые производные пиридонкарбоновой кислоты или их соли
TW200509927A (en) Chronic obstructive pulmonary disease therapeutic agent and method of treating chronic obstructive pulmonary disease using the same
NO20061836L (no) Heksa- og oktahydro-pyndo[1,2-a]pyrazinderlvater med NK1 antagonistisk aktivitet
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.